These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11569284)

  • 1. More blockbusters on the way. Pharmaceutical spending and the impact of pipeline drugs.
    Kaddis A
    Mich Health Hosp; 2001; 37(5):20-3. PubMed ID: 11569284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 4. Surviving the blockbuster syndrome.
    Service RF
    Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
    [No Abstract]   [Full Text] [Related]  

  • 5. Prescription drugs and the changing concentration of health care expenditures.
    Zuvekas SH; Cohen JW
    Health Aff (Millwood); 2007; 26(1):249-57. PubMed ID: 17211035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of pipeline drugs on drug spending growth.
    Mullins CD; Wang J; Palumbo FB; Stuart B
    Health Aff (Millwood); 2001; 20(5):210-5. PubMed ID: 11558705
    [No Abstract]   [Full Text] [Related]  

  • 7. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 9. National trends in prescription drug expenditures and projections for 2021.
    Tichy EM; Hoffman JM; Suda KJ; Rim MH; Tadrous M; Cuellar S; Clark JS; Wiest MD; Matusiak LM; Schumock GT
    Am J Health Syst Pharm; 2021 Jul; 78(14):1294-1308. PubMed ID: 33880494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 11. National health spending in 2007: slower drug spending contributes to lowest rate of overall growth since 1998.
    Hartman M; Martin A; McDonnell P; Catlin A;
    Health Aff (Millwood); 2009; 28(1):246-61. PubMed ID: 19124877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 13. Projecting future drug expenditures--1998.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1998 Jan; 55(2):127-36. PubMed ID: 9465976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving the process of medication budget forecasting.
    Vermeulen LC; Marnocha RM; Thielke TS
    Pharm Pract Manag Q; 1998 Apr; 18(1):72-80. PubMed ID: 10177544
    [No Abstract]   [Full Text] [Related]  

  • 20. Pipeline cherrypicking deal yields lucrative return.
    Ransom J
    Nat Biotechnol; 2006 Jul; 24(7):729. PubMed ID: 16841040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.